A Banner Month: October 2026 Brings a New Approval, Four Practice-Shaping Phase 3 Trials, and a Rewritten Radiation Guideline
Informed Prostate Cancer Support Group Newsletter Special Report · November 2026 · Covering developments of October 2026 A Banner Month: October 2026 Brings a New Approval, Four Practice-Shaping Phase 3 Trials, and a Rewritten Radiation Guideline From Madrid to Washington, the past month delivered progress for men at nearly every stage of the disease — from the biopsy decision to heavily pretreated metastatic cancer. Here is what happened, what the numbers actually say, and what remains unproven. IPCSG Newsletter · Research Roundup · Sources current through November 2, 2026 Every autumn the European Society for Medical Oncology (ESMO) Congress produces a crop of prostate cancer news, but October 2026 was unusually rich. The 2026 congress, held in Madrid from October 23 to 27, featured a prostate cancer trial in its Presidential Symposium, three further practice-relevant phase 3 updates, and first-in-human data on several genuinely new classes of drugs. [10,11,12] On Octob...